Methodologies to objectively assess gait and postural control features in Rett syndrome - With a comment on specific challenges and how to address them

Chuck Layne

Abstract


New pharmacological agents and behavioral interventions designed to ease key symptoms of individuals with Rett syndrome are currently emerging. To carefully evaluate these interventions in this complex and relatively rare disorder, it is paramount to develop robust and objective measures which can be utilized and compared across clinics and research centers.  The ability to compare objectively measured movement data obtained from Rett patients will facilitate assessment of the patient’s performance over time.  It will also increase the potential for Rett-related research centers to share and compare findings thereby increasing the ability to determine if future intervention strategies are effective. This report details an objective data acquisition and analysis protocol of gait and posture that will serve to provide an enhanced evaluation of motoric characteristics of individuals with Rett syndrome than is currently conducted.  To establish the feasibility of this protocol, eighteen females ranging in age from 4 to 20 years participated in three basic tasks: over ground walking, accelerating treadmill walking, and stationary bipedal postural assessment. The feasibility and practicality of obtaining this set of detailed data on gait and posture from individuals with Rett syndrome demonstrates that the protocol can be easily transferred to other gait centers. Even if not all of the assessment components are available it can easily be adapted. We suggest that our assessment protocol can provide a standard for objective assessment in a gait laboratory associated with the diagnosis and treatment of Rett syndrome.


Keywords


Rett, gait, posture, kinematics

Full Text:

PDF

References


Neul JL., Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 2010 Dec; 68(6): 944–950. doi:10.1002/ana.22124. https://www.ncbi.nlm.nih.gov/pubmed/21154482

Temudo T, Ramos E, Dias K, et al. Movement disorders in Rett syndrome: an analysis of 60 patients with detected MECP2 mutation and correlation with mutation type. Mov Disord, 2008 Jul 30;23(10):1384-90. doi: 10.1002/mds.22115.

https://www.ncbi.nlm.nih.gov/pubmed/18512755

Downs JA, Bebbington A, Jacoby P, et al. Gross motor profile in Rett syndrome as determined by video analysis. Neuropediatrics 2008 August; 39(4): 205–210. doi:10.1055/s-0028-1104575. https://www.ncbi.nlm.nih.gov/pubmed/19165708

Downs J, Leonard H, Hill K. Initial assessment of the StepWatch Activity Monitor TM to measure walking activity in Rett syndrome. Disabil Rehabil. 2012; 34(12):1010-5. doi:10.3109/096538288.2011.630773.

https://www.ncbi.nlm.nih.gov/pubmed/22107440

Downs J, Stahlhut M, Wong K, et al. Validating the Rett syndrome Gross Motor Scale. PloS One 2016; 11(1): e0147555. doi:10.1371/journal.pone.0147555.

https://www.ncbi.nlm.nih.gov/pubmed/26800272

Cuddapah VA, Pillai RB, Shekar KV, et al. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet 2014; 51:152–158. doi.org/10.1136/jmedgenet-2013-102113.

https://www.ncbi.nlm.nih.gov/pubmed/24399845

Tarquinio DC, Hou W, Neul JL, et al. The changing face of survival in Rett syndrome and MECP2-related disorders. Pediatr Neurol 2015 Nov; 53(5):402-11.

doi:10.1016/j.pediatrneurol.2015.06.003. https://www.ncbi.nlm.nih.gov/pubmed/26278631

FitzGerald PM, Jankovic J, Percy AK. Rett syndrome and associated movement disorders. Move Disord. 1990; 5(3):195-202.https://www.ncbi.nlm.nih.gov/pubmed/2388636

Chapleau CA, Lane J, Pozzo-Miller L, Percy AK. Evaluation of current pharmacological treatment options in the management of Rett syndrome: from the present to future therapeutic alternatives. Curr Clin Pharmacol 2013 Nov; 8(4):358-69. https://www.ncbi.nlm.nih.gov/pubmed/24050745

Downs J, Leonard H, Jacoby P, Brisco L, Baikie G, Hill K. Rett syndrome: establishing a novel outcome measure for walking activity in an era of clinical trials for rare disorders. Disabil Rehabil 2015; 37(21):1992-6. doi:10.3109/09638288.2014.993436.

https://www.ncbi.nlm.nih.gov/pubmed/25495774

Pozzo-Miller L, Pati S, Percy AK. Rett Syndrome: Reaching for clinical trials. Neurotherapeutics 2015; Jul;12(3): 631-40. doi: 10.1007/s13311-015-0353-y.

https://www.ncbi.nlm.nih.gov/pubmed/25861995

Verschueren SM, Swinnen SP, Desloovere K, Duysens J. Effects of tendon vibration on the spatiotemporal characteristics of human locomotion. Exp Brain Res 2002 Mar; 143(2): 231-9. https://www.ncbi.nlm.nih.gov/pubmed/11880899

Lotan M, Schenker R, Wine J, Downs J. The conductive environment enhances gross motor function of girls with Rett syndrome. A pilot study. Dev Neurorehabil 2012; 15(1):19-25. DOI:10.3109/17518423.2011.629374

https://www.ncbi.nlm.nih.gov/pubmed/22256830

Wang H, Pati S, Pozzo-Miller L. Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes. Front Cell Neurosci; 2015; 9:55. doi:10.3389/fncel.2015.00055

https://www.ncbi.nlm.nih.gov/pubmed/25767435